iDose TR has been designed to deliver therapeutic levels of a proprietary formulation of travoprost from within the eye. Credit: Mihai Moisa / Unsplash.

Glaukos has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for its micro-invasive intraocular implant, iDose TR.

The company designed iDose TR to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for longer periods.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The implant helps address ubiquitous patient non-compliance and chronic side effects related to topical glaucoma medications.

Glaukos chairman and CEO Thomas Burns said: “The submission of the iDose TR NDA represents a significant milestone for our company, resulting from more than a decade of our teams’ unrelenting research, development and clinical efforts to bring this potential game-changing therapy one step closer to patients who may need a new glaucoma treatment alternative.

“We look forward to working closely with the FDA in their pending review process and continue to believe iDose TR can be a transformative novel technology able to fundamentally improve the treatment paradigm for patients with glaucoma.”

The NDA submission includes results from two Phase II pivotal clinical trials that evaluated iDose TR.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Both trials achieved the pre-specified primary efficacy endpoints within three months and also demonstrated favourable safety and tolerability profiles over a 12 months period.

The submission also includes data from the iDose TR exchange trial.

The exchange trial included the removal of the original iDose TR implant as well as a second administration.

The second administration demonstrated a favourable safety profile over an evaluation period of 12 months.

The implant features a new travoprost formulation and is administered using a micro-invasive procedure.

iDose TR can be removed and replaced to provide a long-term dropless alternative to daily treatment with eye drops.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact